Congress reports
Each memo inOncology SPECIAL ISSUE congress report delivers the latest in lung cancer research to come out of a major international oncology congress. Each issue is now translated into Chinese (Mandarin), Spanish, and Japanese. The next SPECIAL ISSUE report will summarise findings presented at the Annual Congress of the European Society for Medical Oncology (ESMO), October 2019.
English
- Preface
- Checkpoint inhibition in non-small-cell lung cancer: expanding the range of options
- EGFR-positive tumors: the issue of optimal therapy across several lines
- Frontline combinations of EGFR- and angiogenesis-targeted agents
- Exploring synergy between anti-angiogenic drugs and immunotherapy
- Innovations in the setting of rare mutations: ALK, ROS1, NTRK, NRG1
- CNS disease does not preclude successful treatment
- Even infrequent actionable drivers are important
- Emerging survival benefits in the small-cell setting
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at ESMO 2019
Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.
Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.
Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.
Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.
Access older Congress Reports here:
ASCO 2019
English
- Preface
- Early-Stage NSLC: promising (neo)adjuvant approaches
- Novel first-line options and other insights in EGFR-mutant lung cancer
- Trial updates and new biomarkers in the field of immunotherapy
- Interview: Blood-based testing in ALK-positive disease
- Rare mutations: taking treatment one step further
- Small-cell tumors: improvements in the second-line setting
- Expansion of clinical trial enrollment criteria: what would we gain?
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Mandarin
- 序言
- 早期NSCLC：有前景的（新）辅助方法
- EGFR突变肺癌的新一线选择和其他见解
- 免疫疗法领域的试验更新和新生物标志物
- ALK阳性疾病基于血液的检测
- 罕见突变：使治疗更进一步
- 小细胞肿瘤：二线条件下的改善
- 扩展临床试验入选标准：我们将有何收获？
- Full Report (Mandarin)
Japanese
- 巻頭言
- 早期NSCLC：期待を持てる（ネオ）アジュバント療法
- EGFR遺伝子変異陽性肺がんへの新規第一選択薬およびその他の知見
- 臨床試験の最新結果および免疫療法の新規バイオマーカー
- ALK融合遺伝子陽性NSCLCにおける血液検体を用いたリキッドバイオプシー
- まれな遺伝子変異：治療を一歩先へ進める
- 小細胞肺がん：セカンドライン治療の改善
- 臨床試験の選択基準の緩和：われわれにとっての利点
- Full Report (Japanese)
Expert interviews at ASCO 2019
Click on the button to load the content from bit.ly.
Dr. Martin Reck gives an overview on where we are today regarding immunotherpaies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.
Click on the button to load the content from bit.ly.
Dr Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future "predictive biomarker algorithm" in lung cancer might look like.
Click on the button to load the content from bit.ly.
Dr. Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.
Click on the button to load the content from bit.ly.
Dr. Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.
ELCC 2019
- Preface
- Current perspectives in EGFR-targeted therapy
- Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity
- Encouraging findings in NTRK-, ROS1- and ALK-positive lung cancer
- Interview: Improving accuracy of lung cancer screening
- Extensive-disease small-cell tumors: signals of activity
- Interview: “We need chemotherapy when rapid responses are required”
- Anti-angiogenic combinations excel in later lines
- Full Report (English)
- Full Report (Japanese)
- Full Report (Mandarin)
Expert interviews at ELCC 2019
Click on the button to load the content from playout.3qsdn.com.
Prof. Garrido gives an overview of the management of patients with stage III NSCLC, novel treatments in stage III disease and recent insights concerning immune modulatory vaccination in patients with NSCLC.
Click on the button to load the content from playout.3qsdn.com.
Dr. Newsom-Davis on the treatment algorithm for ALK-positive NSCLC and future developments for patients with ALK/ROS1-positive tumors.
Click on the button to load the content from playout.3qsdn.com.
Prof. Peled talks about the importance of early detection of lung cancer – especially in poorer countries –, promising biomarkers for the early detection and new insights into the interactions between lung cancer cells and the tumor microenvironment.
Click on the button to load the content from playout.3qsdn.com.
Prof. Dingemans explains the importance of chemotherapy in the current management of NSCLC and promising new combinations of chemotherapeutic agents with other drug classes.
ESMO 2018
English
- Preface
- Checkpoint inhibition excels in all treatment lines
- EGFR-mutant lung cancer: what’s new with respect to activity and resistance?
- Interview: Several reasons support sequencing of EGFR TKI treatment
- Potent treatment options in ALK- and MET-positive disease
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Mandarin
- 序言
- 检查点抑制在所有治疗线中表现优异
- EGFR突变肺癌：活性和耐药性方面新发现
- 专访：支持EGFR TKI治疗用药顺序的若干原因
- ALK和MET阳性疾病的有效治疗选择
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Japanese
- 巻頭言
- すべての治療ラインで免疫チェックポイント阻害薬の優位性が示される
- EGFR遺伝子変異陽性肺がん：活性および抵抗性に関する新たな知見とは？
- インタビュー：EGFR TKI療法の順番を重視するいくつかの理由
- ALK融合遺伝子変異陽性肺がんおよびMET遺伝子変異陽性肺がんへの効果の高い治療選択肢
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at ESMO
Click on the button to load the content from bit.ly.
Dr. Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.
Click on the button to load the content from playout.3qsdn.com.
Dr. Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.
WCLC 2018
English
- Preface
- New data on PD-L1 inhibitor activity and determinants of outcomes in immunotherapy-treated patients
- Emerging standards in tumours with rare genetic drivers
- Anti-EGFR treatment: real-world experience and clinical trial insights
- Interview: Modern agents enable dramatic responses even in phase I trials
- Substantial reduction in lung cancer mortality using volume CT screening: the NELSON trial
- The patient perspective: assessment of quality of life and lung cancer stigma
- Multiple approaches for the treatment and prevention of CNS metastases
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Mandarin
- 序言
- PD-L1抑制剂活性和免疫治疗患者结果的决定因素相关新数据
- 具有罕见遗传驱动肿瘤的新兴标准
- 抗EGFR治疗：实际经验与临床试验见解
- 访谈：新药即使在I期试验中也能产生惊人缓解
- 使用体积CT筛查显著降低肺癌死亡率：NELSON试验
- 患者视角：评估生活质量和肺癌病耻感
- 治疗和预防CNS转移的多种方法
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Japanese
- 巻頭言
- 免疫療法を受ける患者の転帰への抗PD-L1抗体薬の活性および決定因子に関する新データ
- まれなドライバー遺伝子変異のある腫瘍への新しい標準治療
- 抗EGFR抗体薬：実臨床での使用経験と治験で得た感想
- インタビュー：第I相試験であっても新薬には劇的な効果が見られる
- 肺がん検診にボリュームCTを用いることで肺がんの死亡率が大幅に低下：NELSON試験
- 患者の見解：生活の質の評価と肺がんに関わるスティグマ
- CNS転移巣への多様な治療法および予防法
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at WCLC 2018
Click on the button to load the content from playout.3qsdn.com.
Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.
Click on the button to load the content from playout.3qsdn.com.
James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.
Click on the button to load the content from playout.3qsdn.com.
Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.
Click on the button to load the content from playout.3qsdn.com.
Vera Hirsh discusses the latest clinical achievements using EGFR-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.
Click on the button to load the content from playout.3qsdn.com.
Virote Sriuranpong talks about new agents in the area of EGFR-targeted therapy as well as the results obtained with afatinib in a named patient program at Asian centers.
ASCO 2018
- Preface
- PD-(L)1 inhibition alone and in combination: recent insights into immunotherapy
- Immune checkpoint blockade: determinants of treatment success
- New data on EGFR-directed TKIs across 3 generations
- Interview with Barbara Melosky: “The sequencing question remains”
- ALK-positive disease: pushing the borders of treatability
- Recent benchmarks in the management of small-cell tumours
- Comprehensive sequencing of plasma cell-free DNA permits non-invasive cancer detection
- Distinct somatic genome variations in young lung cancer patients
- Full Report (English)
- Full Report (Japanese)
- Full Report (Mandarin)
Expert interviews at ASCO 2018
Click on the button to load the content from playout.3qsdn.com.
Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.
Click on the button to load the content from playout.3qsdn.com.
Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.
Click on the button to load the content from playout.3qsdn.com.
Terufumi Kato talks about the nationwide screening project LC-SCRUM-Japan and the insights that have been obtained through these data in general and regarding squamous-cell lung cancer in particular.
CSCO 2017
English
- Preface
- Guidelines for the treatment of NSCLC in China: progress and controversies
- Diagnosis of EGFR-mutated NSCLC: from guidelines to reality
- Different therapies for treatment of squamous cell carcinoma
- Optimal strategy for the treatment of EGFR-mutant lung cancer
- New insights into the treatment of ALK-mutant-positive NSCLC patients
- Determination of clinical responses to immunotherapy
- Combination of targeted therapy with radiotherapy for treatment of brain metastasis
- Full Report (English)
- Full Report (Mandarin)
Mandarin
- 序言
- 中国NSCLC治疗指南：进展与争议
- EGFR突变NSCLC的诊断：从指南到现实
- 治疗鳞状细胞癌的不同疗法
- 用于治疗EGFR突变肺癌的最佳策略
- ALK突变阳性NSCLC患者治疗新见解
- 免疫疗法临床应答的确定
- 靶向疗法联合放疗用于治疗脑转移
- Full Report (English)
- Full Report (Mandarin)
Expert interviews at CSCO annual meeting
Click on the button to load the content from playout.3qsdn.com.
Caicun Zhou discusses NSCLC care in China, and the use of molecular targeted agents
Click on the button to load the content from playout.3qsdn.com.
Shun Lu discusses the recent clinical trial data for EGFR targeted agents and how this will shape clinical practice, as well as the need for solid clinical trial data revealing how the sequencing of EGFR directed agents affects survival
WCLC 2017
- Preface
- What is new in surgery? Redefining current options
- EGFR TKI therapy in specific populations and settings
- “We are making steady progress toward better lung cancer control”
- Taking anti-EGFR drug treatment further: later lines
- Immunotherapy: novel biomarkers on the horizon & news from pivotal trials
- Approaching squamous-cell carcinoma in a targeted manner
- Malignant mesothelioma: recent data on nintedanib and checkpoint inhibitors
- Chemotherapy: new approaches, new settings
- Survival is the result of lung cancer screening
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at WCLC
Click on the button to load the content from playout.3qsdn.com.
IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.
Click on the button to load the content from playout.3qsdn.com.
IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.
Click on the button to load the content from playout.3qsdn.com.
IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.
Click on the button to load the content from playout.3qsdn.com.
IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.
ESMO 2017
English
- Preface
- Immunotherapy: once more at the cutting edge of progress
- Immunostimulation as a promising approach in SCLC
- Randomised findings on CT-based follow-up after resection of early NSCLC
- EGFR-mutant lung cancer: sequencing as a major topic in light of new data
- Interview: Survival is the result of multiple treatment lines
- Reaching unprecedented outcome dimensions in malignant mesothelioma
- Characteristics and outcomes for SCLC arising from transformation
- ALK-positive NSCLC: updates on crizotinib and alectinib
- Rare driver mutations: BRAF- and HER2-mutant NSCLC
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Mandarin
- 序言
- 免疫疗法：再次处于进步前沿
- 免疫刺激作为有希望的SCLC疗法
- 早期NSCLC切除后基于CT随访的随机化结果
- EGFR突变肺癌：排序根据新数据作为主要话题
- 专访：生存期受到多条治疗线的影响
- 获得前所未有规模的恶性间皮瘤结果
- 转化导致SCLC的特征和结果
- ALK阳性NSCLC：克唑替尼（crizotinib）和艾乐替 尼（alectinib）的更新数据
- 罕见驱动突变：BRAF和HER2突变NSCLC
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Japanese
- 序文
- 免疫療法: 進歩の最先端でもう一度
- SCLCでの有望なアプローチとしての免疫刺激
- 早期NSCLCの切除後のCTベースの経過観察に関する無作為化所見
- EGFR-変異肺癌: 新たなデータを考慮した主要な話題としての優先順位付け
- インタビュー：生存は複数次の治療の結果である
- 悪性中皮腫で前例のない転帰範囲への到達
- 形質転換に起因するSCLCの特性および転帰
- ALK-陽性NSCLC: クリゾチニブおよびアレクチニブに関する最新情報
- 希少ドライバー変異: BRAF-およびHER2-変異NSCLC
- Full Report (English)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at ESMO
Click on the button to load the content from playout.3qsdn.com.
Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.
Click on the button to load the content from playout.3qsdn.com.
Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.
Click on the button to load the content from playout.3qsdn.com.
Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.
Click on the button to load the content from playout.3qsdn.com.
Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.
ASCO 2017
- Preface
- EGFR-targeted treatments: insights from the adjuvant to the resistant setting
- New standards of care for ALK-positive disease
- Reducing the danger that arises from the CNS as a site of progression
- Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications
- Established targeted agents taking root in the HER2-positive setting
- Further defining the optimal use of immune checkpoint inhibitors
- Real-world utility of ctDNA NGS to identify matched targeted therapy
- Interview: Lung cancer in China: hurdles and progress
- Anti-angiogenic and immunotherapeutic approaches in mesothelioma
- Enhancing the profile of KRAS-mutant lung cancer
- Full Report (English)
- Full Report (Japanese)
- Full Report (Mandarin)
Expert interviews at ASCO
Click on the button to load the content from playout.3qsdn.com.
Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.
Click on the button to load the content from playout.3qsdn.com.
Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.
Click on the button to load the content from playout.3qsdn.com.
Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo inOncology, and the approval of afatinib for EGFR+ NSCLC in China.
Click on the button to load the content from playout.3qsdn.com.
Maya Gottfried on NSCLC screening and treatment options
WCLC 2016
- Preface
- Notable advances in the field of anti-EGFR therapy
- Emerging treatments in ALK-positive NSCLC: new options, but also new challenges
- Liquid biopsy in the context of EGFR and other mutations
- Immunotherapy: novel anti-PD-L1 antibodies & various combination regimens
- Who is a candidate for immunotherapy?
- Anti-angiogenesis with nintedanib: activity in mesothelioma, and potential biomarkers
- Practice-changing refinements of lung cancer staging
- Inhibition of HER2 driver mutations can confer benefits
- Full Report (English)
- Full Report (Spanish)
- Full Report (Mandarin)
- Full Report (Japanese)
Expert interviews at WCLC
Click on the button to load the content from playout.3qsdn.com.
Martin Schuler on the current state-of-play for EGFR diagnostic technologies
Click on the button to load the content from playout.3qsdn.com.
Johan Vansteenkiste discusses the practical considerations for immunotherapy
Click on the button to load the content from playout.3qsdn.com.
Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress
Click on the button to load the content from playout.3qsdn.com.
Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer
Click on the button to load the content from playout.3qsdn.com.
James Chih-Hsin Yang talks TKIs
ESMO 2016
- Preface
- Rare driver mutations: encouraging results in small patient populations
- SCLC: genomic alterations pave the way to targeted approaches
- No phase III benefit with selumetinib in KRAS-mutant NSCLC
- EGFR-targeted therapy: at the right time in the right patient
- Targeting angiogenesis can prolong life
- Next-generation ALK inhibitors excel after crizotinib failure
- Immune checkpoint inhibition: the picture is slowly completing itself
- Full Report (English)
- Full Report (Spanish)
- Full Report (Mandarin)
Expert interviews at ESMO
Click on the button to load the content from playout.3qsdn.com.
Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.
Click on the button to load the content from playout.3qsdn.com.
Martin Reck discusses the management of immunotherapy related adverse events.
Click on the button to load the content from playout.3qsdn.com.
Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.
Click on the button to load the content from playout.3qsdn.com.
Anders Mellemgaard on anti-angiogenesis treatments
ASCO 2016
- Preface
- Immunotherapy: updates on clinical trials and other insights
- Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF
- Lung cancer care in Latin America: evolution of modern therapies and challenges to overcome the existing gaps
- Exploring established and novel EGFR-directed agents
- “The importance of first-line and second-line targeted agents is obvious”
- Mutational analysis: on the road to refined standards
- New approaches are raising hope for SCLC patients
- ULTIMATE: chemotherapy plus bevacizumab beyond first line
- Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide
- PFS improvement due to local therapy in oligometastatic NSCLC
- Similar outcomes obtained with four adjuvant cisplatin-based chemotherapy regimens
- Full Report (English)
- Full Report (Spanish)
- Full Report (Mandarin)
ESMO Asia 2015
- Preface
- EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options
- Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?
- Risks and chances in patients with oligometastatic disease
- Immunotherapy: anti-tumour activity despite extensive pretreatment
- PD-L1 expression is a nightmare in terms of complexity
- Immunotherapy: management of toxicity
- Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naïve ALK-positive NSCLC patients
- Full Report (English)
- Full Report (Mandarin)
ECC 2015
- Preface
- News on targeted agents in the advanced setting
- Interview: Liquid biopsy is a revolution
- Pivotal results and sub-analyses in the field of immunotherapy
- Interview: Immunotherapy has opened up a new avenue of research
- Lung cancer screening: diagnosis in the nick of time
- Genomic testing – becoming part of everyday practice
- Optimising treatment in local and regional lung cancer
- Small-cell lung cancer: established and novel approaches
- Full Report
ASCO 2015
- Preface
- Metastatic NSCLC: new drugs and updates on well-known agents
- Interview: “EGFR testing is a reality in central and eastern European countries”
- Immunotherapy: effective treatments gathering on the horizon
- Statement “Select the patients who will be able to benefit”
- Novel approaches in small-cell lung cancer
- Further analyses of biomarkers
- Interview: “These findings will change the standard-of-care”
- Phase III results in local and regional lung cancer
- Full Report